{'fraction_non_alphanumeric': 0.032180209171359615, 'fraction_numerical': 0.0056315366049879325, 'mean_word_length': 5.5473684210526315, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pituitary Adenomas in Children and Adolescents: A Retrospective Single-Centre Analysis

7 ES P E Poster presented at: Figure 3: Serum prolactin concentrations (a) and tumour volume (b) at time of diagnosis and at 3 months, 12 months and at the latest visit after treatment start with cabergoline (PROLA, n=11) Conclusion: Pituitary adenomas (PA) are more frequent in girls than in boys. Prolactinomas (PROLA) are commonest PA even in children. Clinical signs are unspecific in PROLA and incidentalomas (INCA) and secreted hormone specific in adrenocorticotropic-hormone (ACTHA) and growth-hormone (GHA) secreting adenomas. Headaches occur in all forms of PA. Cabergoline is well tolerated in PROLA and reduces clinical symptoms, prolactin serum concentrations and tumour size. Complete tumour resection in ACTHA reverses clinical signs, but may be complicated by secondary adrenal insufficiency and hypopituitarism. Somatostatin analogues improve clinical symptoms in GHA, but barely reduce tumour size. INCA may only require symptomatic treatment. A comprehensive registry for PA is desirable to understand its aetiology and to improve care in paediatrics. Pituitary adenoma in children and adolescents: a retrospective single-centre analysis